Previous close | 165.25 |
Open | N/A |
Bid | 148.45 |
Ask | 153.05 |
Strike | 920.00 |
Expiry date | 2024-05-17 |
Day's range | 165.25 - 165.25 |
Contract range | N/A |
Volume | |
Open interest | 3 |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tuesday, the FDA said it would convene an in-person meeting of the Peripheral and Central Nervous System Drugs Advisory Committee on Monday, June 10, 2024, to discuss Eli Lilly and Co’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease. The open public hearing portion of the meeting will be conducted virtually. The Phase 3 study submitted as part of this application, TRAILBLAZER-ALZ 2, is a double-blind, placebo-controlled study to evaluate the safety and efficacy of donanemab in pa
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.